Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
Microbot Medical (Nasdaq: MBOT) has partnered with Emory University to explore autonomous robotics in endovascular procedures. The collaboration, led by Dr. Amir Pourmorteza, aims to integrate the LIBERTY® Endovascular Robotic Surgical System with imaging technology for autonomous endovascular procedures.
This initiative, known as Project Trita, combines CT-guidance, artificial intelligence, and medical robotics. The goal is to standardize outcomes, improve efficiencies, reduce radiation exposure, and democratize access to top-level healthcare. Microbot Medical's CEO, Harel Gadot, envisions this integration as a step towards creating an autonomous robotic system for endovascular procedures, potentially benefiting millions of patients globally.
Microbot Medical (Nasdaq: MBOT) ha stretto una partnership con l'Università di Emory per esplorare robotica autonoma nelle procedure endovascolari. La collaborazione, guidata dal Dr. Amir Pourmorteza, mira a integrare il Sistema Chirurgico Robotico Endovascolare LIBERTY® con la tecnologia di imaging per procedure endovascolari autonome.
Questa iniziativa, conosciuta come Progetto Trita, combina guida CT, intelligenza artificiale e robotica medica. L'obiettivo è standardizzare i risultati, migliorare l'efficienza, ridurre l'esposizione alle radiazioni e democratizzare l'accesso a cure sanitarie di alto livello. Il CEO di Microbot Medical, Harel Gadot, considera questa integrazione un passo verso la creazione di un sistema robotico autonomo per procedure endovascolari, che potrebbe beneficiare milioni di pazienti a livello globale.
Microbot Medical (Nasdaq: MBOT) se ha asociado con la Universidad de Emory para explorar la robótica autónoma en procedimientos endovasculares. La colaboración, dirigida por el Dr. Amir Pourmorteza, tiene como objetivo integrar el Sistema Quirúrgico Robótico Endovascular LIBERTY® con tecnología de imagen para procedimientos endovasculares autónomos.
Esta iniciativa, conocida como Proyecto Trita, combina guía por tomografía computarizada, inteligencia artificial y robótica médica. El objetivo es estandarizar los resultados, mejorar la eficiencia, reducir la exposición a radiaciones y democratizar el acceso a una atención médica de alto nivel. El CEO de Microbot Medical, Harel Gadot, imagina esta integración como un paso hacia la creación de un sistema robótico autónomo para procedimientos endovasculares, que podría beneficiar a millones de pacientes en todo el mundo.
마이크로봇 메디컬 (Nasdaq: MBOT)이 에모리 대학교와 협력하여 내혈관 수술에서의 자율 로봇 기술을 탐색하고 있습니다. 이번 협업은 아미르 포우르모르테자 박사가 주도하며, LIBERTY® 내혈관 로봇 수술 시스템을 이미징 기술과 통합하여 자율적인 내혈관 수술을 목표로 하고 있습니다.
이 이니셔티브는 프로젝트 트리타로 알려져 있으며, CT 유도, 인공지능 및 의료 로봇 공학을 결합합니다. 목표는 결과 표준화, 효율성 향상, 방사선 노출 감소, 최고 수준의 건강 관리 접근 민주화입니다. 마이크로봇 메디컬의 CEO인 하렐 가돗은 이 통합이 내혈관 수술을 위한 자율 로봇 시스템을 만드는 한 걸음이 될 것으로 보고 있으며, 이는 전 세계 수백만의 환자에게 혜택을 줄 수 있을 것입니다.
Microbot Medical (Nasdaq: MBOT) s'est associé à l'Université d'Emory pour explorer la robotique autonome dans les procédures endovasculaires. La collaboration, dirigée par le Dr Amir Pourmorteza, vise à intégrer le Système Chirurgical Robotique Endovasculaire LIBERTY® avec la technologie d'imagerie pour des procédures endovasculaires autonomes.
Cette initiative, connue sous le nom de Projet Trita, combine l'orientation par tomodensitométrie, l'intelligence artificielle et la robotique médicale. L'objectif est d'uniformiser les résultats, d'améliorer l'efficacité, de réduire l'exposition aux radiations et de démocratiser l'accès à des soins de santé de haut niveau. Le PDG de Microbot Medical, Harel Gadot, envisage cette intégration comme un pas vers la création d'un système robotique autonome pour les procédures endovasculaires, pouvant potentiellement bénéficier à des millions de patients dans le monde entier.
Microbot Medical (Nasdaq: MBOT) hat eine Partnerschaft mit der Emory University gegründet, um autonome Robotik bei endovaskulären Verfahren zu erforschen. Die Zusammenarbeit, geleitet von Dr. Amir Pourmorteza, zielt darauf ab, das LIBERTY® Endovaskuläre Robotisch-Chirurgische System mit Bildgebungstechnologie für autonome endovaskuläre Verfahren zu integrieren.
Diese Initiative, bekannt als Projekt Trita, kombiniert CT-gesteuerte Verfahren, künstliche Intelligenz und medizinische Robotik. Das Ziel ist es, Ergebnisse zu standardisieren, Effizienz zu steigern, Strahlenexposition zu reduzieren und den Zugang zu hochwertiger Gesundheitsversorgung zu demokratisieren. Der CEO von Microbot Medical, Harel Gadot, sieht diese Integration als einen Schritt zur Schaffung eines autonomen Robotersystems für endovaskuläre Eingriffe, das potenziell Millionen von Patienten weltweit zugutekommen könnte.
- Partnership with Emory University to explore autonomous robotics in endovascular procedures
- Potential to standardize outcomes and improve healthcare access
- Integration of LIBERTY® system with imaging technology for autonomous procedures
- None.
The collaboration between Microbot Medical and Emory University marks a significant step towards advancing autonomous robotics in endovascular procedures. This partnership has the potential to revolutionize the field of minimally invasive surgery, with far-reaching implications for both patients and healthcare providers.
The integration of Microbot's LIBERTY® Endovascular Robotic Surgical System with imaging technology could lead to several key advancements:
- Standardization of procedures: Autonomous systems could reduce variability in surgical outcomes, potentially improving overall patient care.
- Increased efficiency: Streamlined workflows and reduced procedure times could lead to cost savings and increased patient throughput.
- Reduced radiation exposure: Automated systems may minimize the need for prolonged fluoroscopy, benefiting both patients and medical staff.
- Improved access to care: Standardized autonomous systems could potentially enable more hospitals to offer advanced endovascular procedures, even in areas with specialist availability.
However, it's important to note that this agreement is still in the evaluation phase. The path from concept to market-ready autonomous surgical systems is long and complex, involving rigorous testing, regulatory approvals and potential hurdles in clinical adoption. Investors should view this as a long-term strategic move rather than an immediate revenue driver.
While the potential is exciting, Microbot Medical will need to navigate significant challenges, including ensuring system reliability, addressing liability concerns and gaining acceptance from the medical community. The success of this initiative could position Microbot as a leader in autonomous surgical robotics, but it's important to monitor progress closely and assess the company's ability to execute on this vision.
This collaboration agreement between Microbot Medical and Emory University represents a strategic move that could significantly impact the company's long-term prospects. While the immediate financial implications are likely minimal, the potential for future value creation is substantial.
Key financial considerations include:
- R&D Investment: Microbot may need to allocate additional resources to support this research initiative, potentially impacting short-term profitability but enhancing long-term growth potential.
- Market Expansion: Success in developing autonomous capabilities could dramatically expand Microbot's addressable market, potentially driving future revenue growth.
- Competitive Advantage: Being at the forefront of autonomous surgical robotics could provide Microbot with a significant competitive edge in the rapidly evolving medical device market.
- Intellectual Property: Any breakthroughs resulting from this collaboration could lead to valuable patents, strengthening Microbot's IP portfolio and potentially creating new licensing opportunities.
However, investors should be cautious. The path to commercialization for autonomous surgical systems is long and uncertain. Regulatory hurdles, clinical trials and market adoption challenges could all impact the timeline and ultimate success of this initiative.
Furthermore, as a small-cap company (
In conclusion, while this collaboration has significant potential, it's important for investors to view it as a long-term strategic initiative rather than a near-term value driver. The stock may see some positive sentiment on this news, but material financial impact is likely years away.
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system
BRAINTREE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced it has entered into an agreement with Emory University, which will allow the parties to evaluate and explore the potential for a future collaboration in connection with autonomous robotics in endovascular procedures. Under the terms of the agreement, Emory University will assume the responsibility of exploring the feasibility of integrating the LIBERTY® Endovascular Robotic Surgical System with an imaging system to create an autonomous robotic system for endovascular procedures. Amir Pourmorteza, PhD, Assistant Professor in the Department of Radiology and Imaging Sciences at Emory University Winship Cancer Institute, and Department of Biomedical Engineering at Georgia Institute of Technology, will lead the evaluation under Project Trita.
“Autonomous robotics has the potential to standardize outcomes, improve efficiencies, reduce radiation exposure, and democratize access to top-level healthcare,” commented Dr. Pourmorteza. “Project Trita merges CT-guidance, artificial intelligence, and medical Robotics. I am excited to work with Microbot Medical on this project.”
“Our vision for the future of endovascular robotics includes autonomous capabilities, which has the potential to standardize endovascular procedures and improve access to benefit millions of patients globally. We believe LIBERTY® can be integrated with imaging, planning and navigation software to ultimately create an autonomous robotic system that can be used in endovascular procedures,” said Harel Gadot, CEO, President and Chairman of Microbot Medical. “We’re excited to work with Dr. Pourmorteza who is a leader in this space and we believe he shares a similar vision.”
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.
The Investigational LIBERTY® Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY® Endovascular Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures.
Further information about Microbot Medical is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic Surgical System, the outcome of its studies to evaluate the LIBERTY® Endovascular Robotic Surgical System, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, including whether the Company’s pivotal study in humans is successful, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, any lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty
FAQ
What is the purpose of Microbot Medical's collaboration with Emory University?
Who is leading the evaluation of MBOT's LIBERTY® system at Emory University?
What are the potential benefits of autonomous robotics in endovascular procedures according to MBOT?
What is Project Trita in relation to Microbot Medical (MBOT)?
